| Pyrrolopyrimidine JAK coreAbstract pharmacophorejak-pyrrolopyrimidine-corePage | Scaffold | c1cc2c(ncnc2[nH]1)N | — | — | JAK · core · Shared pharmacophore / core scaffold. Anchor for the JAK inhibitor chemical series lineage… |
| Baricitinib (Olumiant)Verified drugbaricitinibPage | Drug | CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(c3c2ncnc3N)c… | Pyrrolopyrimidine JAK core | 17%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · JAK1/2 · Approved therapeutic. Baricitinib (Olumiant) in this family map. |
| Fedratinib (Inrebic)Verified drugfedratinibPage | Drug | CC1=CC(=CC(=C1)Nc2nc(Nc3ccc(OCCN4CCCC4)cc3… | Pyrrolopyrimidine JAK core | 10%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · JAK2 · Approved therapeutic. Fedratinib (Inrebic) in this family map. |
| Ruxolitinib (Jakafi)Verified drugruxolitinibPage | Drug | N#CC[C@H](C1CCCC1)n2cc(c3c2ncnc3N)c4ccccc4 | Pyrrolopyrimidine JAK core | 18%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · JAK1/2 · Approved therapeutic. Ruxolitinib (Jakafi) in this family map. |
| Tofacitinib (Xeljanz)Verified drugtofacitinibPage | Drug | C[C@@H]1CCN(C[C@@H]1N(C)c2ncnc3[nH]ccc23)C… | Pyrrolopyrimidine JAK core | 28%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · JAK1/3 · Approved therapeutic. Tofacitinib (Xeljanz) in this family map. |
| Upadacitinib (Rinvoq)Verified drugupadacitinibPage | Drug | C[C@@H]1CCN(C[C@@H]1Nc2ncnc3[nH]ccc23)C(=O… | Pyrrolopyrimidine JAK core | 27%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · JAK1 · Approved therapeutic. Upadacitinib (Rinvoq) in this family map. |